From the other side of the consultation, briefly.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

jason_paloalto said:

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

6 month update on cardiovascular risk: down 64 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

One thing that is still open after jason_paloalto’s answer:

Did your prescriber agree with that reading, and if not what was their objection?

bri_stats said:

6 month update on cardiovascular risk: down 64 lbs, off blood pressure meds, A1C normalized.

Senior perspective on cardiovascular risk: I'm 63 years old and started this journey skeptically. My geriatrician recommended it after years of failed interventions.

13 months later: down 36 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Tagging this one for the weekly digest.